22.05.2022 Views

DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Table 9–1

Some Pharmacological Properties of Choline Esters and Natural Alkaloids

MUSCARINIC ACTIVITY

MUSCARINIC SUSCEPTIBILITY TO Cardio- Gastro- Urinary Eye Antagonism NICOTINIC

AGONIST CHOLINESTERASES vascular intestinal Bladder (Topical) by Atropine ACTIVITY

Acetylcholine +++ ++ ++ ++ + +++ ++

Methacholine + +++ ++ ++ + +++ +

Carbachol – + +++ +++ ++ + +++

Bethanechol – ± +++ +++ ++ +++ –

Muscarine a – ++ +++ +++ ++ +++ –

Pilocarpine – + +++ +++ ++ +++ –

a

Not used therapeutically

The major natural alkaloid muscarinic agonists—

muscarine, pilocarpine, and arecoline—have the same

principal sites of action as the choline esters. Muscarine

acts almost exclusively at muscarinic receptor sites, and

the classification of these receptors derives from the

actions of this alkaloid. Pilocarpine has a dominant muscarinic

action but is a partial rather than a full agonist;

the sweat glands are particularly sensitive to pilocarpine.

Arecoline also acts at nicotinic receptors. Although

these naturally occurring alkaloids are of great value as

pharmacological tools and muscarine has toxicological

significance (discussed later), present clinical use is

restricted largely to the employment of pilocarpine as a

sialagogue and miotic agent (Chapter 64).

History and Sources. The alkaloid muscarine was isolated from the

mushroom Amanita muscaria by Schmiedeberg in 1869; its toxicology

is discussed later. Pilocarpine is the chief alkaloid obtained from

the leaflets of South American shrubs of the genus Pilocarpus.

Although it was long known by the natives that the chewing of leaves

of Pilocarpus plants caused salivation, the first experiments were

apparently performed in 1874 by the Brazilian physician Coutinhou.

The alkaloid was isolated in 1875, and shortly thereafter the actions

of pilocarpine on the pupil and on the sweat and salivary glands were

described by Weber. Arecoline is the chief alkaloid of areca or betel

nuts, the seeds of Areca catechu. The red-staining betel nut is consumed

as a euphoretic by the natives of the Indian subcontinent and

East Indies in a masticatory mixture known as betel and composed

of the nut, shell lime, and leaves of Piper betle, a climbing species

of pepper. Methacholine was synthesized and studied by Hunt and

Taveau as early as 1911. Carbachol and bethanechol were synthesized

and investigated in the 1930s.

Absorption, Distribution,

and Elimination

The absorption and distribution of these compounds

may be predicted from their structures: muscarine and

the choline esters are quaternary amines; pilocarpine

and arecoline are tertiary amines (Figure 9–1).

Because they are quaternary amines, the choline

esters are poorly absorbed following oral administration

and have a limited ability to cross the blood-brain

barrier. Even though these drugs resist hydrolysis, the

choline esters are short-acting agents due to rapid elimination

by the kidneys.

Pilocarpine and arecoline, being tertiary amines,

are readily absorbed and can cross the blood-brain barrier.

In contrast, muscarine, a quaternary amine, is

poorly absorbed. Muscarine can still, however, be toxic

when ingested and can even have CNS effects.

Although the specific metabolic pathways have not

been elucidated, pilocarpine clearance is decreased in

patients with hepatic impairment, in whom doses may

need to be reduced. The natural alkaloids are primarily

eliminated by the kidneys; excretion of the tertiary

amines can be accelerated by acidification of the urine.

Therapeutic Uses of Muscarinic

Receptor Agonists

Muscarinic agonists are currently used in the treatment

of urinary bladder disorders and xerostomia and in the

diagnosis of bronchial hyperreactivity. They are also

used in ophthalmology as miotic agents and for the

treatment of glaucoma.

There is growing interest in the role of muscarinic

receptors in cognition. The potential utility of M 1

agonists

in treating the cognitive impairment associated

with Alzheimer’s disease has long been considered.

Other receptor subtypes including M 2

and M 5

also

appear to be involved in the regulation of cognitive

function, at least in animal models (Wess et al., 2007).

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!